Monique M. van Oostaijen-Ten Dam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Monique M. van Oostaijen-Ten Dam has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Amairelys Belen Barroeta Seijas
Institute of Molecular Biology and Pathology National Research Council (CNR) Rome Italy
1 shared publication Andrea Biondi
Pediatric Hematology Department, Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), University of Milano Bicocca, Monza, Italy
1 shared publicationArjan C. Lankester
Pediatric Stem Cell Transplantation Unit, Department of Pediatrics, Leiden University Medical Center, Willem Alexander Children’s Hospital, Leiden, The Netherlands
1 shared publication- Arjan C. Lankester
Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, the Netherlands
1 shared publication - Bo Yuan
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX
1 shared publication - Claire Booth
UCL GOSH Institute of Child Health, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 28 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (8) , 2786-2800
Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT
Defects in B-cell reconstitution upon hematopoietic stem cell (HSC) transplant (HSCT) are a common observation, yet the mechanism remains unexplained. The bone marrow (BM) stroma, including mesenchymal stromal cells (MSCs), guides HSC maintenance and B-lymphopoiesis by secreting crucial cytokines. We report acquired, permanent, selective, and complete B-cell deficiency in the context of full donor chimerism in a patient with X-linked lymphoproliferative disease, and aimed to identify the contribution of the BM microenvironment in disrupted B-cell reconstitution after HSCT. We studied longitudinal BM samples from the patient and his identical twin, both of whom underwent HSCT with the same donor with opposite outcomes in B-cell reconstitution. In the BM of the index patient, we observed progressive loss of proliferation of HSCs and a selective block at the pre-BI cell stage. In vitro modeling studies showed limited survival of patient HSCs and a relative accumulation of pre-B cells. Patient-derived MSCs failed to support survival and proliferation of HSCs and B-cell development of healthy HSCs, which was correlated with reduced CXCL12 levels. Using bulk RNA-sequencing of MSCs and in vitro functional studies, we showed global changes in the patients’ MSCs, and a progressive loss of CXCL12 expression. Indeed, survival of the patients’ HSCs improved upon supplementing the in vitro development culture with CXCL12, suggesting a contribution of defective CXCL12 signaling to the phenotype. In summary, our data show that an acquired defect in the BM-stromal microenvironment and exhaustion of HSCs and committed progenitors may cause a permanent nonpermissive state for normal B-cell development.
- 28 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (8) , 2786-2800
Open AccessAcquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT
Defects in B-cell reconstitution upon hematopoietic stem cell (HSC) transplant (HSCT) are a common observation, yet the mechanism remains unexplained. The bone marrow (BM) stroma, including mesenchymal stromal cells (MSCs), guides HSC maintenance and B-lymphopoiesis by secreting crucial cytokines. We report acquired, permanent, selective, and complete B-cell deficiency in the context of full donor chimerism in a patient with X-linked lymphoproliferative disease, and aimed to identify the contribution of the BM microenvironment in disrupted B-cell reconstitution after HSCT. We studied longitudinal BM samples from the patient and his identical twin, both of whom underwent HSCT with the same donor with opposite outcomes in B-cell reconstitution. In the BM of the index patient, we observed progressive loss of proliferation of HSCs and a selective block at the pre-BI cell stage. In vitro modeling studies showed limited survival of patient HSCs and a relative accumulation of pre-B cells. Patient-derived MSCs failed to support survival and proliferation of HSCs and B-cell development of healthy HSCs, which was correlated with reduced CXCL12 levels. Using bulk RNA-sequencing of MSCs and in vitro functional studies, we showed global changes in the patients’ MSCs, and a progressive loss of CXCL12 expression. Indeed, survival of the patients’ HSCs improved upon supplementing the in vitro development culture with CXCL12, suggesting a contribution of defective CXCL12 signaling to the phenotype. In summary, our data show that an acquired defect in the BM-stromal microenvironment and exhaustion of HSCs and committed progenitors may cause a permanent nonpermissive state for normal B-cell development.
- Open Access
Immunophenotyping of T cells Combined with Vβ antibodies identifies long lasting CMV related T cell Expansions with a consistent TIGIT and PD-1 phenotype
Simultaneous analysis of T cell receptor repertoire and T cell phenotype is of high relevance to gain a deeper understanding on the T cell response in terms of differentiation, kinetics and persistence. Also it is currently unknown how the repertoire of immune checkpoints on T cells evolves over time. To fully capture the heterogenous response, TCR repertoire and T cell phenotype analysis is preferably performed at the single-cell level, but this is costly and analytically challenging. Therefore, we developed a flow cytometry based method that allows for simultaneous characterization of the T cell TCR Vβ and the phenotype. We generated a 9-tube 24-color panel with antibodies against maturation and activation markers, and 24 TCR Vβ chains. Peripheral blood mononuclear cells from 5 healthy controls were analyzed, revealing the presence of oligoclonal expansions. Within the CD27+CD28+ memory T cell population, oligoclonal expansions were characterized by a T regulatory, or KLRG1+CCR7-CD27low phenotype. Within the late CD27- and/or CD28-memory T cells, the populations with the lowest TCR Vβ diversity expressed CX3CR1. As a proof of principle, we demonstrate the dynamics of circulating oligoclonal T cell expansions that emerged following hematopoietic stem cell transplantation in the presence of CMV in 2 patients. We provide evidence that oligoclonal T cells transferred from donor to recipient can be traced up to at least 2.5 years while maintaining its phenotype. Mostly TIGIT and PD-1 were critical in defining T cell expansions, while CD45RA, CD57, CD56 and NKG2A were variably expressed. Overall, we developed a phenotype based method to trace T cell populations, that is widely applicable to different settings in which the T cell response needs to be monitored.
Open AccessImmunophenotyping of T cells Combined with Vβ antibodies identifies long lasting CMV related T cell Expansions with a consistent TIGIT and PD-1 phenotype
Simultaneous analysis of T cell receptor repertoire and T cell phenotype is of high relevance to gain a deeper understanding on the T cell response in terms of differentiation, kinetics and persistence. Also it is currently unknown how the repertoire of immune checkpoints on T cells evolves over time. To fully capture the heterogenous response, TCR repertoire and T cell phenotype analysis is preferably performed at the single-cell level, but this is costly and analytically challenging. Therefore, we developed a flow cytometry based method that allows for simultaneous characterization of the T cell TCR Vβ and the phenotype. We generated a 9-tube 24-color panel with antibodies against maturation and activation markers, and 24 TCR Vβ chains. Peripheral blood mononuclear cells from 5 healthy controls were analyzed, revealing the presence of oligoclonal expansions. Within the CD27+CD28+ memory T cell population, oligoclonal expansions were characterized by a T regulatory, or KLRG1+CCR7-CD27low phenotype. Within the late CD27- and/or CD28-memory T cells, the populations with the lowest TCR Vβ diversity expressed CX3CR1. As a proof of principle, we demonstrate the dynamics of circulating oligoclonal T cell expansions that emerged following hematopoietic stem cell transplantation in the presence of CMV in 2 patients. We provide evidence that oligoclonal T cells transferred from donor to recipient can be traced up to at least 2.5 years while maintaining its phenotype. Mostly TIGIT and PD-1 were critical in defining T cell expansions, while CD45RA, CD57, CD56 and NKG2A were variably expressed. Overall, we developed a phenotype based method to trace T cell populations, that is widely applicable to different settings in which the T cell response needs to be monitored.
- Open Access
- 28 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (4) , 493-499
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency
Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobulinemia, recurrent infections, and hypertrophic cardiomyopathy (HCM). Two of them also presented with intermittent or severe chronic neutropenia. We identified homozygous or compound-heterozygous variants in the gene for folliculin interacting protein 1 (FNIP1), leading to loss of the FNIP1 protein. B-cell metabolism, including mitochondrial numbers and activity and phosphatidylinositol 3-kinase/AKT pathway, was impaired. These defects recapitulated the Fnip1−/− animal model. Moreover, we identified either uniparental disomy or copy-number variants (CNVs) in 2 patients, expanding the variant spectrum of this novel inborn error of immunity. The results indicate that FNIP1 deficiency can be caused by complex genetic mechanisms and support the clinical utility of exome sequencing and CNV analysis in patients with broad phenotypes, including agammaglobulinemia and HCM. FNIP1 deficiency is a novel inborn error of immunity characterized by early and severe B-cell development defect, agammaglobulinemia, variable neutropenia, and HCM. Our findings elucidate a functional and relevant role of FNIP1 in B-cell development and metabolism and potentially neutrophil activity.
- 28 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (4) , 493-499
Open AccessAbsent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency
Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobulinemia, recurrent infections, and hypertrophic cardiomyopathy (HCM). Two of them also presented with intermittent or severe chronic neutropenia. We identified homozygous or compound-heterozygous variants in the gene for folliculin interacting protein 1 (FNIP1), leading to loss of the FNIP1 protein. B-cell metabolism, including mitochondrial numbers and activity and phosphatidylinositol 3-kinase/AKT pathway, was impaired. These defects recapitulated the Fnip1−/− animal model. Moreover, we identified either uniparental disomy or copy-number variants (CNVs) in 2 patients, expanding the variant spectrum of this novel inborn error of immunity. The results indicate that FNIP1 deficiency can be caused by complex genetic mechanisms and support the clinical utility of exome sequencing and CNV analysis in patients with broad phenotypes, including agammaglobulinemia and HCM. FNIP1 deficiency is a novel inborn error of immunity characterized by early and severe B-cell development defect, agammaglobulinemia, variable neutropenia, and HCM. Our findings elucidate a functional and relevant role of FNIP1 in B-cell development and metabolism and potentially neutrophil activity.